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Hypoxia and inﬂammation are closely intertwined phenomena. Critically ill patients often suffer from systemic
inﬂammatory conditions and concurrently experience short-lived hypoxia. We evaluated the effects of short-
term hypoxia on systemic inﬂammation, and show that it potently attenuates pro-inﬂammatory cytokine re-
sponses during murine endotoxemia. These effects are independent of hypoxia-inducible factors (HIFs), but in-
volve augmented adenosine levels, in turn resulting in an adenosine 2B receptor-mediated post-transcriptional
increase of interleukin (IL)-10 production. We translated our ﬁndings to humans using the experimental
endotoxemia model, where short-term hypoxia resulted in enhanced plasma concentrations of adenosine, aug-
mentation of endotoxin-induced circulating IL-10 levels, and concurrent attenuation of the pro-inﬂammatory cy-
tokine response. Again, HIFs were shown not to be involved. Taken together, we demonstrate that short-term
hypoxia dampens the systemic pro-inﬂammatory cytokine response through enhanced purinergic signaling in
mice and men. These effects may contribute to outcome and provide leads for immunomodulatory treatment
strategies for critically ill patients.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Hypoxia and inﬂammation are two closely linked phenomena that
are encountered in many pathological processes; particularly in critical
illness such as sepsis and trauma (reviewed in [12, 41]). Inﬂammation
can lead to tissue hypoxia due to both enhanced demand and decreased
availability of oxygen, the latter resulting from edema, microthrombi
and changes in microcirculation (reviewed in [12]). Conversely, in
vitro studies have demonstrated that hypoxia inﬂuences the immune
response aswell, with either pro- or anti-inﬂammatory effects, depend-
ing on the cell type (reviewed in [25]). In vivo data on immunomodula-
tory effects of hypoxia or hypoxia mimetics in animal models are
conﬂicting. For instance, chronic hypoxia (11–27 days) in mice was re-
ported to result in enhanced TNFα levels upon challenge with endo-
toxin [2], whereas the hypoxia mimetic DMOG was shown to exert
distinct anti-inﬂammatory effects in endotoxemic mice [19]. A recent
study in mice revealed that long-term hypoxia (N12 h) does not rele-
vantly affect the immune response, but increasesmorbidity andmortal-
ity from skin and pulmonary infections [47]. Importantly however,
hypoxia is often very short-lived in critically ill patients, as it is quickly
corrected by oxygen supplementation and/or mechanical ventilation
[31], but the immunologic effects of short-term hypoxia are unknown.
Furthermore, no human data on immunomodulatory effects of hypoxia
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are available. These are nevertheless of clinical relevance, because the
majority of critically ill patients suffer from inﬂammation-related condi-
tions, and putative immunomodulatory effects of short-term hypoxia
might therefore contribute to the outcome of these patients.
Hypoxia may modulate the immune response through a group of
transcription factors called hypoxia-inducible factors (HIFs) [33].
There are several HIF isoforms, of which primarily HIF-1α has been im-
plicated in regulation of the inﬂammatory response [33], although HIF-
2α was also found to have immunomodulatory properties [23]. More-
over, hypoxia also induces enhanced signaling of the purine nucleoside
adenosine [9], which has been shown to exert anti-inﬂammatory and
tissue-protective effects [14]. In addition, adenosine signaling is also
augmented by inﬂammation, through enhanced plasma levels of aden-
osine and increased expression of adenosine receptors. Therefore, hyp-
oxia and inﬂammation might have additive or even synergistic effects
on adenosine signaling [38].
In the present work, we evaluated the immunologic effects of short-
term hypoxia in vivo in mice. Furthermore, we investigated the involve-
ment of HIFs and adenosine signaling in these effects, and translated our
ﬁndings to the human setting using an in vivomodel of systemic inﬂam-
mation in healthy volunteers.
2. Materials and Methods
2.1. Murine Studies
2.1.1. Animals and Ethics
Experiments were performed at the Experimental Centre at the Uni-
versity of Technology Dresden (Medical Faculty, University Hospital
Carl-Gustav Carus), Germany, and the Radboud university in Nijmegen,
the Netherlands. Experiments were in accordance with the facility
guidelines at the University of Technology Dresden and were approved
by the Landesdirektion Dresden, or with the requirements of the Dutch
Experiments on Animals Act and the EC Directive 86/609, and approved
by the Animal Ethics Committee of the Radboud university. Experi-
ments were performed on male C57BL/6 mice (Charles River Laborato-
ries International, Inc., L'Arbresle Cedex, France). For the experiments
depicted in Fig. 3, Vav:cre [44] HIF1f/f [40] and HIF2f/f [18] transgenic
mouse lines were obtained from the Jackson Laboratories (Bar Harbor,
ME) and crossed in our facility. The obtained mouse lines are respec-
tively: Vav:cre-HIF1αf/f (hematopoietic HIF1f/f) and Vav:cre-HIF2αf/f
(hematopoietic HIF2f/f). The degree of HIF1α deﬁciency in hematopoi-
etic cells of Vav:cre-HIF1αf/f mice versusWT littermates was deﬁned by
qPCR on CD45+ bone marrow cells, which revealed N90% reduction of
WT HIF1α mRNA compared to WT littermates (Fig. S1). Since HIF2α
messenger was scarcely detectable in hematopoietic cells of WT mice,
we performed genomic PCRs on DNA isolated from mature white
blood cells. In samples displaying Cre-recombinase, HIF2α PCRs re-
vealed virtually full recombination of the ﬂoxed-HIF2α (Fig. S1). For
the experiments depicted in Figs. 4 and 5, adenosine 2B receptorf/f (pro-
vided by Prof. Eltzschig), and B6.129P2-Il10tm1Cgn/J mice ((MGI Cat#
5470153, RRID:MGI:5470153) (IL-10−/−, The Jackson Laboratory, Bar
Harbor, ME) and genetically matched controls were used (all C57BL/6
background). Due to the nature of the studies, blinding of the animal re-
searchers was not possible. The laboratory analyses were performed by
blinded personnel.
2.2. Experimental Protocol
After randomization using the sealed envelope method, mice were
placed in an air-tight cage that was continuously ﬂushed with either
medical air (normoxia) or an hypoxic nitrogen/medical air mixture
(fraction of inspired oxygen [FiO2] of 9%) at the same airﬂow rate. Endo-
toxin (E. coli, serotype 0111:B4, Sigma-Aldrich, St Louis, MO, USA) dis-
solved in normal saline was administered intraperitoneally at a dose
of 5 mg/kg. Mice were sacriﬁced by exsanguination through orbita
extraction under deep isoﬂurane anesthesia. Bloodwas collected in eth-
ylenediaminetetraacetic acid (EDTA)-containing tubes, centrifuged
(14,000 g, 5 min, room temperature), was and plasma was stored at
−80 °C until analysis. Splenic tissue was snap-frozen in liquid nitrogen
and stored at−80 °C until analysis.
2.3. Cytokine Analysis
Plasma concentrations of TNF, IL-1β, IL-6, KC, and IL-10 were mea-
sured using a Luminex assay (Milliplex, Merck Millipore, Billerica, MA,
USA) or ELISA (Duoset or Quantikine, R&D systems, Minneapolis, MN,
USA).
2.4. mRNA Expression Analysis
Spleen tissue was homogenized using a Tissuelyzer LT instrument
(Qiagen, Venlo, the Netherlands) and RNAwas isolatedwith the RNeasy
kit (Qiagen). Up to 1 μg of RNAwas used for cDNA synthesis with iScript
(Bio-Rad, Veenendaal, the Netherlands).
qPCR was performed on a CFX96 (Bio-Rad, Hercules, CA, USA). The
following primer-probe sets were used (all from Life Technologies, Carls-
bad, CA, USA): TNF: Mm00443258_m1, IL-1β: Mm00434228_m1, IL-6:
Mm00446190_m1, KC: Mm04207460_m1, IL-10: Mm00439614_m1,
VEGF (Mm00437306_m1), B2M (Mm00437762_m1) and HRPT
(Mm01545399_m1). ΔCt values were calculated as the difference be-
tween the Ct value of the target gene and the geometric mean of the Ct
values of two housekeeping genes (B2M and HRPT). Fold regulation
(2|ΔΔCt|) was determined by normalizing ΔCt to the reference group
(normoxia-saline).
2.5. Tissue Adenosine Measurements
Nucleosideswere extracted from spleen tissue by soniﬁcation in 850
μL of ice cold 0.4 N perchloric acid. The mixture was vortexed and 10 μL
of this solution was used for protein assay. The remaining volume was
centrifuged at 14000 rpm at 4 °C for 10 min and 710 μL of the superna-
tant was vortexed with 40 μL phenol red (0.1 mg/mL in water) and
356ul 0.6NKHCO3/KOH. After addition of 111 μL ammoniumphosphate
and 50 μL of 0.18 N H3PO4 the sample was vortexed, and centrifuged at
14000 rpm for 5 min. 1000 uL of the supernatant was used for adeno-
sine measurements by HPLC [26].
2.6. Human Studies
2.6.1. Subjects and Study Design
The human experiments were carried out in two phases
(ClinicalTrials.gov identiﬁers NCT01889823 and NCT01978158) for
safety reasons. All experimentswere in accordancewith the declaration
of Helsinki. After approval from the local ethics committee of the
Radboud University Medical Center, thirty healthy, male volunteers
gave written informed consent to participate in the experiments. Sub-
jects were screened and had a normal physical examination, electrocar-
diography, and routine laboratory. Exclusion criteria were febrile illness
during the 2weeks before the experiment, high altitude exposure in the
threemonths prior to the experiment, use of prescription drugs, history
of spontaneous vagal collapse, and participation in a previous trial with
endotoxin administration.
In the ﬁrst phase, effects of short-termhypoxia in the absence of sys-
temic inﬂammation were studied. Ten subjects were exposed to hyp-
oxia for 3.5 h by titration of FiO2 to a peripheral saturation (SaO2) of
80–85%, using an nitrogen/medical air mixture and an air-tight respira-
tory helmet (CaStar, StarMed, Italy). The airﬂow was adjusted to pre-
vent carbon dioxide rebreating and prevent hypercapnia. In the
second phase, 20 subjects participated in endotoxemia experiments.
These subjects were randomized using the sealed envelope method to
hypoxia (n = 10) as described above, or normoxia (medical air, FiO2
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of 21%, also using the respiratory helmet and the same airﬂow rate as in
hypoxic subjects, n = 10). One hour after initiation of hypoxia or
normoxia, 2 ng/kg U.S. Reference Escherichia coli endotoxin (serotype
O:113, Clinical Center Reference Endotoxin, National Institute of Health,
Bethesda, USA) was administered intravenously to elicit a systemic in-
ﬂammatory response. Due to continuous monitoring of SaO2, blinding
of the researchers performing the procedures on the healthy volunteers
was not possible. All laboratory analyses were performed by blinded
personnel. A depiction of the experimental setup is provided in Fig. S2.
2.6.2. Procedures and Recording of Vital Signs
Subjects refrained from caffeine and alcohol 24 h before the experi-
ment, and refrained from food and drinks 10 h before the experiment. A
venous cannula was placed for ﬂuid infusion (prehydration with 1.5 L
2.5% glucose/0.45% saline in the hour preceding endotoxin administra-
tion followed by hydration with 150 mL/h for 6 h, and 75 mL/h for the
rest of the experiment) and endotoxin administration. An arterial can-
nulawas placed formonitoring of blood pressure and bloodwithdrawal.
Heart rate and SaO2 were monitored using a three-lead electrocardio-
gramand a pulse oximeter connected to a PhilipsMP50patientmonitor.
Body temperature was measured every 30 min using an infrared tym-
panic thermometer (FirstTemp Genius 2; Covidien, Ireland).
2.6.3. Plasma Cytokines and PaO2 Measurements
Blood was collected in EDTA tubes and centrifuged immediately at
2000 g at 4 °C for 10 min after which plasma was stored at −80 °C
until analysis by Luminex assay (Milliplex). PaO2 was analyzed in lith-
ium heparin anticoagulated arterial blood using CG4+ cartridges and
a point-of-care i-STAT blood gas analyzer (Abbott, Abbott Park, IL, USA).
2.6.4. HIF-1α Protein Expression in Leukocytes
After lysis of erythrocytes in lithium heparin-anticoagulated blood
using Pharm Lyse solution (Becton Dickinson, San Jose, CA), surface
staining was performed using ﬂuorochrome-conjugated antibodies
(CD15-FITC (Clone H198), CD3-PECγ7 (Clone HIT3a), CD14-APC
(CloneM5E2) (BioLegend Cat# 301807, RRID:AB_314189) (all obtained
from BioLegend, San Diego, USA) for neutrophils, lymphocytes, and
monocytes, respectively. After ﬁxation and permeabilization with Tran-
scription Factor Fixation/Permeabilization buffer (eBioscience Inc., San
Diego, USA), PE-conjugated anti-HIF-1α and corresponding isotype
control (Clone 241812, RD Systems, Minneapolis, USA)were used to
stain intracellular HIF-1α and correct for aspeciﬁc binding. Leukocytes
were ﬁxed and stored overnight in PBS containing 1% bovine serum al-
bumin and 1% paraformaldehyde. The data were acquired with
Cytomics FC500 (Beckman Coulter, Brea, CA, USA) and analyzed with
Kaluza software (Beckman Coulter). Cell subtypes were identiﬁed by
surface staining and sideward scatter. Mean PE ﬂuorescence, after sub-
traction of isotype-ﬂuorescence, was used as a measure of HIF-1α ex-
pression. The gating strategy used is depicted in Fig. S3.
2.6.5. mRNA Expression of HIF-1α, and Hypoxia Signaling-Related Genes
Blood was collected in PAXgene tubes (PreAnalytiX, Venlo, The Neth-
erlands), which contain a proprietary reagent that immediately stabilizes
leukocyte RNA at the moment of blood withdrawal, and kept at room
temperature for 24 h before storage at−80 °C. Total RNA was isolated
using the PAXgene Blood RNA kit (PreAnalytiX) and up to 1 μg of RNA
was reverse transcribed into cDNA using the i-script cDNA synthesis kit
(Biorad), and stored at−20 °C until analysis. mRNA expression of HIF-
1α was analyzed with qPCR on a Bio-Rad CFX96 (Bio-Rad). HIF-1α ex-
pression was normalized to the expression of the housekeeping gene
B2M. The following primer-probe sets were used (from Life Technolo-
gies): HIF-1α: Hs00153153_m1 and B2M: Hs00984230_m1.
Expression of hypoxia signaling-related genes was analyzed in 3
subjects from each group using the RT2 Proﬁler hypoxia signaling Plus
PCR Array (Qiagen) according to the manufacturer's protocol on a
CFX96 (Bio-Rad). The array plate was customized by replacing 4
controls by 4 extra genes (VonHippel Lindau [VHL], granulocytemacro-
phage colony-stimulating factor [GM-CSF], granulocyte colony-stimu-
lating factor [G-CSF] and soluble VEGF receptor [FLT1]). Genes of
interest were normalized to 4 housekeeping genes (GAPDH, B2M,
RPLP0 and ACTB) present on the PCR array. A b35 cycles cut off was
applied.
2.6.6. Plasma Adenosine Measurements
Plasma adenosine concentrations were measured using an in-house
developed method described previously [36]. Brieﬂy, blood was imme-
diately mixed at the tip of the syringe with a 2.5 mL solution containing
pharmacological blockers of adenosine formation, transport and degra-
dation.Blood samples were centrifuged for 10 min at 1000 g at 4 °C and
plasma was stored at−80 °C until analysis. Plasma adenosine concen-
trations were determined by high performance liquid chromatography
(HPLC).
2.7. Whole Blood Stimulation Experiments
After approval from the local ethics committee of the Radboud uni-
versity medical center (CMO 2010/10), lithium heparin-anticoagulated
bloodwas obtained from8healthy volunteerswhoprovidedwritten in-
formed consent. Blood was diluted 5 times in culture medium (RPMI
[Invitrogen, Carlsbad, California, USA] supplemented with 10 μg/mL
gentamicin, 10 mM Glutamax and 10 mM pyruvate) and incubated in
48-well plates in the presence of 1 or 10 μMPSB1115 (Tocris BioScience,
Abingdon, UK) or vehicle (DMSO, ﬁnal concentration of 0.1% in all ex-
perimental conditions) for 30 min at 37 °C and 5% CO2. Hereafter, 10
μM 5′-N-Ethylcarboxamidoadenosine (NECA) or vehicle (DMSO) was
added and cultures were again incubated for 30 min. Subsequently,
10 ng/mL endotoxin (E. coli, serotype O55:B5, Sigma Aldrich) or vehicle
(RPMI) was added and cultures were incubated for 24 h, after which
plates were centrifuged for 8 min at 1400 RPM at room temperature
and supernatant collected and stored at−80 °C until analysis. Cytokine
concentrations were measured using ELISA according to the manufac-
turer's instructions (Human Duoset, R&D systems).
2.8. Calculations and Statistical Analysis
For both the human and murine experiments a power calculations
were performed. In previous human endotoxemia experiments per-
formed by our group, the standard deviation (s.d.) for peak plasma
TNF concentration was 30% of the mean. Using an two-sided α of 0.05,
a power of 80% (β of 0.2), and an expected detectable contrast of 40%
in an unpaired t-test design, 10 subjects per group were required.
For the initial murine experiments, a provisional power calculations
were based on previous murine endotoxemia experiments performed
by our group, the s.d. for plasma IL-6 concentration was 25% of the
mean. Using an two-sided α of 0.05, a power of 80% (β of 0.2), and an
expected detectable contrast of 40% in an unpaired t-test design, 8 ani-
mals per groupwere required. To reduce the number of animals needed,
we used the data from the primary murine experiment to calculate the
lowest number of animals necessary. Plasma IL-6 concentrations were
normally distributed, with a mean of 38,019 pg/mL in the normoxic
group, and 11,126 pg/mL in the hypoxia group, and a pooled standard
deviation of 6994. A 2-group 2-sided power calculation with these ac-
tual data shows that n=2would be sufﬁcient to identify this difference.
Nevertheless, we deemed this group size insufﬁcient to draw robust
conclusions and therefore have used a minimum of n= 5 for all endo-
toxin-treated groups. Because saline treatment was shown to not in-
duce cytokine responses under normoxic or hypoxic conditions, we
applied the ‘reﬁnement’ dogma; by reducing the number of animals in
this group to n = 2–6. Data are presented as median and interquartile
range, or mean (±s.e.m.) based on their distribution (calculated by
the Shapiro-Wilk test). Differences between groups in demographic
characteristics were calculated using Kruskall-Wallis tests. Except for
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demographic characteristics, all non-parametric data were log-trans-
formed before statistical analysis The human in vivo cytokine data
were analyzed using unpaired Student's t-tests on Area Under Curve
(AUC) of time-concentration curves to assess differences in total
amount of cytokines released. For other human in vivo data, repeated
measures one-way analysis of variance (ANOVA) followed by Dunnett's
post-hoc test was used to assess within-group differences over time and
make comparisons to baseline, whereas between-group differences
over timewere assessed using repeatedmeasures two-wayANOVA (in-
teraction term). Independent groups were compared using Student's t-
test, multiple independent groups were compared using one way
ANOVA with Dunnett's post-hoc test to compare with control group.
All tests were two-sided, and a p-value of b0.05 was considered statisti-
cally signiﬁcant. Statistical calculationswere performed usingGraphPad
Prism version 5.0 (GraphPad Software, San Diego, CA, USA).
For the RT2 Proﬁler hypoxia signaling Plus PCR Array data, differences
between groups were analyzed using repeated measures two-way
ANOVA (interaction term) on ΔCT values. To analyze differences over
time within one group or in the pooled dataset of hypoxic and normoxic
endotoxemic subjects, paired Student t-tests were used on ΔCT values,
comparing the different time-points against baseline (t=−1, just before
initiation of hypoxia or normoxia using the respiratory helmet). A 2-fold
change cut off compared to baseline was applied and p-values were
corrected for the false discovery rate (FDR) using Benjamini Hochberg
correction. qPCR array data were analyzed using TIGR Multiexperiment
viewer 4.0 (TMeV4.0) and are presented as fold change compared to
baseline.
3. Results
3.1. Short-term hypoxia exerts anti-inﬂammatory effects during murine
endotoxemia
Binding of lipopolysaccharide (LPS, endotoxin) to Toll-like receptor 4
is a critical step in orchestrating of the inﬂammatory response in Gram-
negative sepsis, and increased levels of plasma cytokines are one of the
key hallmarks of this response. We used a murine model in which intra-
peritoneal injectionwith E. coli-derived endotoxinwas employed to elicit
a systemic inﬂammatory response, and studied the effects of short-term
hypoxia (fraction of inspired oxygen [FiO2] of 9%) on the systemic cyto-
kine response (experimental design depicted in Fig. 1a). Plasma levels
of both pro- (tumor necrosis factor alpha [TNF], interleukin-1β [IL-1β],
IL-6, and keratinocyte-derived chemokine [KC]) and anti- inﬂammatory
(IL-10) cytokines were increased at both 1.5 and 3 h after endotoxin ad-
ministration (Fig. 1b). Hypoxia initiated 1 h before endotoxin administra-
tion resulted in profound augmentation of plasma IL-10 levels and
attenuation of the pro-inﬂammatory cytokine response (Fig. 1b). These
effects were most pronounced at 1.5 h after endotoxin administration
(Fig. 1b), and were present to a similar extent when mice were chal-
lenged with lower doses of endotoxin (Fig. 1c and d).
3.2. The Effects of Short-Term Hypoxia Are Rapidly Constituted and Post-
Transcriptionally Regulated
Subsequently, we assessed the time window during which hypoxia
exerts the observed anti-inﬂammatory effects by varying the timing of
hypoxia relative to endotoxin administration (experimental design
depicted in Fig. 2a). Except for TNF, which was not affected, the previ-
ously found anti-inﬂammatory phenotype was also observed when
hypoxia was initiated at the time of endotoxin administration (“simul-
taneous” condition, Fig. 2b). In contrast, anti-inﬂammatory effects
were neither identiﬁed when hypoxia was applied only in the hour be-
fore endotoxin administration (hypoxia “pretreatment” condition), nor
when it was initiated 0.5 h after endotoxin administration (hypoxia
“posttreatment” condition, Fig. 2b). From these results, we infer that
the ﬁrst 30 min following endotoxin administration are critical for the
anti-inﬂammatory effects of short-term hypoxia. To investigate
whether these effects are transcriptionally regulated, we measured
mRNA expression of IL-10, TNF, IL-1β, IL-6 and KC in splenic tissue (ex-
perimental design depicted in Fig. 2c). In mice that were not challenged
with endotoxin, hypoxia alone did not affect expression of any of the
genes, except for a slight but signiﬁcant decrease in TNF mRNA
(Fig. 2d). Expression of all cytokine genes was strongly induced by en-
dotoxin administration, but was not attenuated by hypoxia (Fig. 2d);
TNF mRNA levels were even slightly enhanced. To ascertain that the
spleen becomes hypoxic in our model, we also determined mRNA ex-
pression of the classic hypoxia-induced gene vascular endothelial
growth factor (VEGF). As depicted in Fig. S4, hypoxia signiﬁcantly in-
creased VEGF expression, both in the presence and absence of endo-
toxin-induced inﬂammation.
3.3. Hypoxia Inducible Factors Are Not Involved in the Anti-Inﬂammatory
Effects of Short-Term Hypoxia
Previous studies have revealed that hypoxia-inducible transcription
factors (HIFs) are involved in regulation of immune responses [33]. To
evaluate the involvement of HIFs in the anti-inﬂammatory effect of
short-term hypoxia, we performed hypoxia experiments in mice deﬁ-
cient for HIF1α or HIF2α in their hematopoietic system and wild type
littermates (experimental design depicted in Fig. 3a). As shown in Fig.
3b, hematopoietic deletion of HIF1α or HIF2α did not relevantly affect
the hypoxia-induced differences in cytokine responses compared to
wild type mice. These results indicate no involvement of hematopoietic
HIF1α or HIF2α in the anti-inﬂammatory effects of short-term hypoxia,
which is in line with the previous ﬁnding that these effects are post-
transcriptionally mediated.
3.4. Short-TermHypoxia Augments Adenosine Levels and Adenosine 2B Re-
ceptor-Dependent IL-10 Production
Purinergic signaling plays a critical role in adaptation to hypoxia. In
vitro and ex vivo studies have shown that hypoxia as well as inﬂamma-
tion leads to increased levels of the anti-inﬂammatory and tissue-pro-
tective purine adenosine [3, 6, 9, 38, 46]. In addition, inﬂammation
also increases the expression of adenosine receptors [38]. Thismay indi-
cate that hypoxia and inﬂammation have additive or synergistic effects
on adenosine signaling. Previous in vitrowork revealed that stimulation
of adenosine 2B (A2B) receptors results in increased IL-10 production
via a post-transcriptional mechanism [30]. Therefore, we hypothesized
that short-term hypoxia results in a rapid increase in adenosine, leading
to an early and profound increase in plasma IL-10 levels through en-
hanced A2B receptor signaling, ultimately resulting in dampening of
the pro-inﬂammatory cytokine response. To test these hypotheses, we
ﬁrst measured tissue adenosine levels during hypoxia, systemic inﬂam-
mation and the combination of both conditions (experimental design
depicted in Fig. 4a). Hypoxia in the absence of inﬂammation enhanced
splenic levels of adenosine within 30 min, further increasing after
1.5 h of hypoxia (Fig. 4b). Systemic inﬂammation also increased adeno-
sine levels, and concurrent hypoxia resulted in a synergistic increase
(Fig. 4b).
Hereafter, we assessed the involvement of the A2B receptor in the
observed enhanced IL-10 levels and subsequent attenuation of the
pro-inﬂammatory cytokine response using germline-deﬁcient A2B
receptor mice and genetically matched controls (experimental design
depicted in Fig. 4c). The hypoxia-induced increase in plasma IL-10
observed in wild type mice was nulliﬁed in A2B-deﬁcient mice
(Fig. 4d). Furthermore, the hypoxia-induced attenuation of IL-1β and
KC was less pronounced and did not reach statistical signiﬁcance in
these mice, whereas the trend towards lower TNF levels was absent
(Fig. 4d). Thus, the adenosine 2B receptor is crucial for the enhanced
IL-10 levels induced by short-term hypoxia. Because IL-10 potently at-
tenuates pro-inﬂammatory cytokine production during endotoxemia
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inmice [22] andhumans [32],we evaluatedwhether IL-10 is involved in
the hypoxia-induced attenuation of pro-inﬂammatory cytokines. To this
end, we performed experiments in germline IL-10-deﬁcient mice (ex-
perimental design depicted in Fig. 5a). In these mice, the hypoxia-in-
duced anti-inﬂammatory phenotype less pronounced for IL-1β and
absent for IL-6 and KC (Fig. 5b).
3.5. Short-Term Hypoxia Dampens the Endotoxin-Induced Pro-Inﬂamma-
tory Cytokine Response in Humans in vivo
To translate our ﬁndings obtained inmice to humans, we performed
hypoxia experiments in healthy volunteers who were intravenously
injected with endotoxin. Thirty healthy subjects were exposed to either
Fig. 1. Short-term hypoxia exerts anti-inﬂammatory effects duringmurine endotoxemia. (a) Experimental setup. C57BL/6micewere randomized to short-term hypoxia or normoxia and
intraperitoneally (i.p) injected with endotoxin (5 mg/kg) or saline. (b) Plasma concentrations of interleukin-10 (IL-10), tumor necrosis factor alpha (TNF), IL-1β, IL-6 and keratinocyte-
derived chemokine (KC). n = 4 in saline groups, n = 8 in endotoxin groups. (c) Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and
intraperitoneally injected with endotoxin (5, 0.5 or 0.05 mg/kg). (d). Plasma concentrations of IL-10, TNF, IL-1β, IL-6 and KC. n= 5 per group. Data expressed as mean (± s.e.m.). *P b
.05,**P b .01, ***P b .001, #P= .05–0.10 (unpaired Student's t-test).
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endotoxemia alone, hypoxia (target peripheral saturation [SaO2] of 80–
85%) alone, or hypoxia combinedwith endotoxemia. (See Fig. 6a for the
experimental design, Fig. S2 for a depiction of the experimental setup,
and Table S1 for demographic characteristics of the study subjects).
Hypoxia (FiO2 of 11–12%) resulted in decreased arterial oxygen pres-
sures accomplishing the peripheral saturation (SaO2) target of 80–
85%, with a concurrent decrease in mean arterial pressure and an in-
crease in heart rate (Fig. 6b). Hypoxia waswell-tolerated and no serious
adverse events occurred during the study. In the hypoxia-only group,
plasma cytokine concentrations were below the lower detection limit
throughout the experiment, indicating that short-term hypoxia exerts
no inﬂammatory effects by itself (Fig. 6c). Endotoxin administration
elicited a typical systemic inﬂammatory response characterized by an
increase in body temperature (Δ temperature 1.6 ± 0 0.2 °C in both
groups, mean ± s.e.m.) and ﬂu-like symptoms. Furthermore, plasma
concentrations of TNF, IL-6, IL-8, and IL-10 increased profoundly after
endotoxin administration (Fig. 6c). Hypoxia during endotoxemia re-
sulted in an early and two-fold increase of IL-10 compared with the
normoxia group, while pro-inﬂammatory cytokine levels were attenu-
ated by 30 to 50% (Fig. 6c).
3.6. Hypoxia Does Not Affect Leukocyte HIF-1αmRNA and Protein Expres-
sion, and HIF Activity in Humans
Although HIFs were not involved in the anti-inﬂammatory effects of
short-term hypoxia in mice, we nevertheless assessed the possible in-
volvement of these transcription factors in the human setting. To this
end, we measured HIF-1αmRNA and protein expression in circulating
leukocytes. HIF-1α mRNA in leukocytes and HIF-1α protein levels in
neutrophils and lymphocytes, but not monocytes, increased after endo-
toxin administration (Fig. 7a–d). This endotoxin-induced increase in
HIF-1α expression is in line with previous in vitro studies showing
that endotoxin induces HIF-1α activity under normoxic conditions
[35]. Hypoxia in the presence and absence of endotoxemia did not affect
HIF-1αmRNA and protein expression (Fig. 7a). In addition, we assessed
hypoxia-induced transcriptional activity by determining the expression
of 86 hypoxia-signaling-related genes in leukocytes, many of which are
downstream targets of HIFs. This analysis revealed no signiﬁcant
changes in expression of any of the genes in the hypoxia only group.
Furthermore, there were no signiﬁcant differences in expression of
any of the genes between hypoxic and normoxic endotoxemic subjects
(Table S2). Taken together, short-term hypoxia neither results in en-
hanced HIF-1α levels, nor in HIF-dependent transcriptional activity in
circulating leukocytes.
3.7. Short-Term Hypoxia Augments Plasma Adenosine Levels in Humans in
vivo
Plasma adenosine levels were measured to evaluate the role of this
purine in the human experiments. Hypoxia in the absence of systemic
inﬂammation resulted in a signiﬁcant increase in plasma adenosine
levels at the end of the hypoxic period (t = 2.5 h, Fig. 7e), which nor-
malized after reoxygenation. Systemic inﬂammation in the presence
as well as the absence of hypoxia resulted in a more prolonged increase
in plasma adenosine levels.
3.8. A2B Receptor Stimulation in Human Whole Blood Mimics the Anti-In-
ﬂammatory Effects of Hypoxia
Finally, to investigate the involvement of the A2B receptor in the
human setting, we stimulated human whole blood with endotoxin in
the presence or absence of the nonselective adenosine receptor agonist
5′-N-Ethylcarboxamidoadenosine (NECA) and the selective human A2B
receptor antagonist PSB1115. As depicted in Fig. 8a, NECA potently
Fig. 2. The anti-inﬂammatory effects of short-term hypoxia are rapidly constituted and post-transcriptionally regulated. (a) Experimental setup. C57BL/6 mice were randomized to
normoxia or one of the following hypoxia modalities: hypoxic control: hypoxia starting 1 h before endotoxin administration until 1.5 h thereafter; simultaneous: hypoxia starting
simultaneous with endotoxin administration until 1.5 h thereafter; pretreatment: hypoxia only in the hour before endotoxin administration; posttreatment: hypoxia starting 0.5 h
after endotoxin administration until 1.5 h thereafter. Endotoxin (5 mg/kg) was injected intraperitoneally (i.p). (b) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. (c)
Experimental setup. C57BL/6 mice were randomized to short-term hypoxia or normoxia and intraperitoneally injected with endotoxin (5 mg/kg) or saline. (d) mRNA expression of IL-
10, TNF, IL-1β, IL-6 and KC measured in splenic tissue. n = 8 per group in all experiments. Data expressed as mean (± s.e.m.) or mean (± s.e.m.) fold change related to normoxic-
saline condition on a 2log scale. *P b .05, **P b .01, ***P b .001 (compared to normoxia calculated using one-way ANOVA with post-hoc Dunnett's test for panel b; unpaired Student's t-
test for panel d).
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enhanced IL-10 production, while attenuating TNF and IL-6 release. A2B
receptor blockade partially counteracted NECA's effects on IL-10 and
TNF.
Taken together, our data reveal that short-term hypoxia dampens
the endotoxin-induced systemic inﬂammatory response through a
rapid increase in adenosine levels, resulting in an A2B-receptor depen-
dent increase of IL-10 concentrations and subsequent attenuation of
pro-inﬂammatory cytokines (Fig. 8b).
4. Discussion
Hypoxia and inﬂammation are key characteristics ofmanypatholog-
ical processes, and they inﬂuence each other considerably. Herein, we
demonstrate that short-term hypoxia exerts profound anti-inﬂamma-
tory effects during systemic inﬂammation in vivo in both mice and
humans. The underlying mechanism involves enhanced adenosine
release and stimulation of the adenosine A2B receptor, resulting in
augmented IL-10 production and subsequent dampening of the pro-
inﬂammatory cytokine response. Our data further demonstrate that
HIFs are not involved in the immunologic effects of short-term hypoxia.
Previous work demonstrated that hypoxia increases extracellular
adenosine concentrations in vitro [3] and ex vivo [6, 9, 46]. We show
that clinically relevant levels of hypoxia result in a rapid increase of
adenosine levels in vivo, in both humans andmice. Hypoxia can enhance
extracellular adenosine levels through several pathways. During cellular
stress, such as hypoxia or inﬂammation, precursor nucleotides (e.g.
ATP) are released, and hypoxia enhances their conversion to adenosine
[13]. In addition, hypoxia inhibits adenosine uptake of the equilibrative-
nucleotide-transporter [10]. Nevertheless, both these processes take
several hours to constitute, as they involve alterations of the transcrip-
tion and translation of the proteins involved. However, in ex vivo exper-
iments, hypoxia was shown to attenuate adenosine kinase activity
within minutes, resulting in a rapid increase of extracellular adenosine
[9, 46]. It appears plausible that this mechanism accounts for the swift
hypoxia-induced increase of adenosine in the present work.
We identify that the hypoxia-induced enhanced IL-10 production is
mediated via an A2B receptor-dependent post-transcriptional
Fig. 3. The anti-inﬂammatory effects of short-term hypoxia are not mediated through HIFs. (a) Experimental setup. Vav:cre HIF-1αf/f,Vav:cre HIF-2αf/f and genetically matchedwild type
littermates (C57BL/6 background) were exposed to short-term hypoxia and intraperitoneally (i.p.) injected with endotoxin (5 mg/kg). (b) Plasma concentration of IL-10, TNF, IL-1β, IL-6
andKC.n=6–7 inVav:creHIF-1αf/f andwild type groups, n=6–8 inVav:cre HIF-2αf/f andwild typegroups. Data are expressed asmean (±s.e.m.). *P b .05, **P b .01, ***Pb .001 (unpaired
Student's t-test).
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Fig. 4. The anti-inﬂammatory effects of short-term hypoxia involve adenosine 2B receptor-dependent augmentation of IL-10 levels. (a) Experimental setup. C57BL/6micewere randomized to
short-termhypoxia or normoxia and intraperitoneally (i.p.) injectedwith endotoxin (5mg/kg) or saline. (b) Splenic tissue concentrationof adenosine. n=6 in saline groups, n=8 in endotoxin
groups. (c) Experimental setup. Adenosine 2B receptor (A2B) genetic deﬁcient and genetically matched control mice (C57BL/6 background) were randomized to short-term hypoxia or
normoxia and intraperitoneally injected with endotoxin (5 mg/kg) or saline. (d) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. n= 2 in saline groups, n = 6 in wild type endotoxin
groups, n = 8 in A2B −/− normoxic endotoxin group, n = 7 in normoxic endotoxin A2B−/− group. Data are expressed as mean (±s.e.m.). *P b .05, **P b .01, ***P b .001, # P = .05–0.1
(unpaired Student's t-test).
Fig. 5.Hypoxia-induced attenuation of pro-inﬂammatory cytokines involves IL-10. (a) Experimental setup. IL-10−/− and geneticallymatchedwild type mice (C57BL/6 background) were
randomized to short-termhypoxia or normoxia and intraperitoneally (i.p.) injectedwith endotoxin (5mg/kg) or saline. (b) Plasma concentration of IL-10, TNF, IL-1β, IL-6 and KC. n=3 in
wild type saline groups, n = 4 in IL-10−/− saline groups, n = 8 in all endotoxin groups. Data expressed as mean (±s.e.m.). **P b .01, ***P b .001 (unpaired Student's t-test).
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mechanism;ﬁndingswhich are corroborated by our in vitrodata obtained
in human leukocytes. Furthermore, anti-inﬂammatory effects through
A2B receptor signaling have been reported by others. For example, mice
deﬁcient for A2B display an augmented TNF response after renal ischemia
and reperfusion [17], and increased inﬂux and delayed clearance of neu-
trophils in a lung injury model [27]. Along these lines, an important role
for A2B receptors in improving outcome was demonstrated in murine
models of pleural inﬂammation [8], renal [17], intestinal [20], and hepatic
[5] ischemia-reperfusion, andmultimicrobial abdominal sepsis [7]. Previ-
ous human work is in support of the identiﬁed adenosine-induced IL-10-
dependent anti-inﬂammatory effects. First, the infusion of recombinant
IL-10 during human endotoxemia resulted in decreased plasma concen-
trations of pro-inﬂammatory cytokines [28]. Second, treatment with the
adenosine reuptake inhibitor dipyridamole during human endotoxemia
caused an early and pronounced increase of plasma IL-10 levels and at-
tenuation of TNF and IL-6 plasma concentrations [37]. In contrast, intrave-
nous infusion of adenosine during human endotoxemia did not result in a
clear anti-inﬂammatory phenotype [42, 43]. Thismay be explained by the
fact that adenosine infusion started 30 min after endotoxin administra-
tion in these studies, whereas we show that the ﬁrst 30 min are critical
for its anti-inﬂammatorily effects. In addition, plasma adenosine is
known to have a very short half-life [39], and the infused adenosine
may therefore not have reached the target tissue. It needs to be acknowl-
edged that although A2B and IL-10 deﬁcient mice clearly display attenu-
ation of the hypoxia-induced anti-inﬂammatory phenotype, it was not
completely abrogated, implying that othermechanismsmay also contrib-
ute to hypoxia-induced anti-inﬂammatory effects, albeit to a much lesser
extent.
Fig. 6. Short-termhypoxia dampens the endotoxin-inducedpro-inﬂammatory cytokine response in humans. (a) Experimental setup.Healthy volunteerswere randomized to either short-term
hypoxia or normoxia in combination with intravenous administration of 2 ng/kg endotoxin to elicit systemic inﬂammation, or to short-term hypoxia without endotoxin administration. (b)
Arterial oxygen pressure (PaO2) peripheral oxygen saturation (SaO2), mean arterial pressure (MAP) and heart rate (HR). (c) IL-10, TNF, IL-6 and IL-8 plasma concentrations over time and
area under the time-concentration curves (AUC). The blue shaded box indicates the period of hypoxia. Data are expressed as mean (± s.e.m.). P-values indicate the difference between the
AUCs of the normoxic endotoxemia and hypoxic endotoxemia groups, calculated using unpaired Student's t-tests. *P b .05, **P b .01, ***P b .001. n= 10 per group.
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We found no involvement of HIFs in the anti-inﬂammatory effects of
short-term hypoxia. Our initial murine data revealed that the anti-in-
ﬂammatory effects exerted by short-term hypoxia are very rapid and
post-transcriptionally regulated, already rendering the critical involve-
ment of a transcription factor unlikely, and the subsequent experiments
in hematopoietic HIF-1α- and HIF-2α-deﬁcient mice conﬁrm this. Nev-
ertheless, it needs to be acknowledged that HIFs are known to exert im-
munomodulatory effects, but that these mainly appear to be of
relevance in the setting of chronic hypoxia. For example, a recent mu-
rine study showed that prolonged hypoxia (12 h up to several days)
in the context of a concurrent skin or pulmonary infection leads to in-
creased morbidity and mortality, in a HIF-dependent manner [47]. An-
other study, in which mice were exposed to hypoxia for 11–27 days,
demonstrated an enhanced plasma TNFα response upon challenge
with endotoxin [2]. Theseﬁndings signify that distinctly differentmech-
anisms underlie the effects of short-term and chronic hypoxia. Finally,
administration of the hypoxia-mimetic DMOG, a prolyl hydroxylase in-
hibitor which stabilizes HIFs, resulted in a similar anti-inﬂammatory cy-
tokine proﬁle in endotoxemic mice as observed in the present study,
although the in vivo involvement of HIFs was not determined and
Fig. 7. Short-term hypoxia neither affects leukocyte HIF-1α mRNA and protein expression, nor HIF transcriptional activity, and augments plasma adenosine levels in humans.
Measurements were performed on samples obtained from the experiments depicted in Fig. 6a. (a) Leukocyte HIF-1α mRNA change over time expressed as change from baseline
(timepoint -1, just before initiation of hypoxia or normoxia using the respiratory helmet) on a 2log scale. (b, c and d) Change in neutrophil, monocyte and lymphocyte HIF-1α protein
expression over time as measured by ﬂow cytometry. Neutrophils, monocytes, and lymphocytes were identiﬁed with CD15, CD14, and CD3 ﬂuorochrome-conjugated antibodies,
respectively. Intracellular HIF-1α protein expression is expressed as the difference between mean ﬂuorescence intensity (MFI) of HIF-1α antibody-stained and isotype control-stained
cells. The gating strategy is provided in Fig. S3. (e) Plasma concentrations of adenosine. Data are expressed as median [IQR]. Within-group changes over time were analyzed using one
way ANOVA followed by Dunnett's post-hoc test on log-transformed data. Between-group differences over time were analyzed using repeated measures two-way ANOVA on log
transformed data (interaction term). *P b .05, **P b .01, ***P b .001 compared to baseline (timepoint -1 h). HE; hypoxic endotoxemia, NE; normoxic endotoxemia, H; hypoxia. MFI;
mean ﬂuorescence intensity. n = 10 per group.
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additional off-target effects cannot be excluded when using these phar-
macological mimetics [19].
Our work demonstrates that short-term hypoxia attenuates the in-
ﬂammatory response in vivo consistently across species. The relevance
of hypoxia-induced anti-inﬂammation remains to be determined, but
speculatively, it may represent a mechanism aimed at limiting inﬂam-
mation-induced tissue injury, thereby improving outcome of severe in-
fections with concurrent tissue hypoxia. Hosts can respond to invading
pathogens by mounting an immunologic response, which may result in
collateral damage known as immunopathology [16, 29]. Tolerance to
the consequences of pathogen invasion and immunopathology are
mechanisms that provide an effective adaptation to disease. As such,
hypoxia-induced anti-inﬂammation may represent a mechanism to
improve the host's tolerance to immunopathology, and theoretically,
accepting or inducing systemic hypoxia could therefore curtail exces-
sive inﬂammation. Previous implementation studies [21, 45] and clini-
cal trials [15, 34] have demonstrated safety and feasibility of
conservative oxygenation strategies in the intensive care unit (ICU),
paving the way for further exploration of variable oxygenation targets.
Intriguingly, recentwork revealed that short-lived hypoxia at the emer-
gency department appeared to be associated with a lower mortality
compared to normoxia or hyperoxia [31]. In that study, patients in the
hypoxia group displayed a median PaO2 of 54 mmHg (7.7 kPa) at the
emergency department [31], which is in the same range as what the
hypoxic subjects were exposed to in our study. Based on the data pre-
sented in the presentwork, it is tempting to speculate that this observed
beneﬁcial effect on outcome is due to reduced immunopathology.
Nevertheless, wewish to emphasize that caution should be taken in vul-
nerable patients due to the risk of inadequate tissue oxygenation and
organ failure. The adenosine signaling pathwaymay therefore represent
another therapeutic target. Unfortunately, direct systemic infusion of
adenosine as an immunomodulatory therapy is limited by its short
half-life [39] and undesired cardiovascular side effects [24]. Direct, un-
selective pharmacologic stimulation of adenosine receptors may result
in a similar harmful proﬁle. Theoretically, allosteric modulation of the
A2B receptor, thereby increasing its binding afﬁnity and/or functional
efﬁcacy, may be more successful. Under physiologic conditions with
low levels of adenosine, the adenosine receptor is not activated,
preventing its disadvantageous systemic effects. Under local inﬂamma-
tory or hypoxic conditions however, tissue levels of adenosine increase,
and the allosterically modulated A2B receptor will be more sensitive to
adenosine and/or cause stronger anti-inﬂammatory effects at similar
adenosine concentrations, resulting in site-speciﬁc anti-inﬂammatory
effects [1] without systemic side effects. Although the development of
this class of drugs is in its infancy, efforts aimed at pharmacologic
targeting of the adenosine signaling pathway to achieve anti-inﬂamma-
tory effects are being made [4, 11].
In conclusion, we demonstrate that short-term hypoxia profoundly
attenuates the pro-inﬂammatory cytokine response during systemic in-
ﬂammation inmice, and translate these ﬁndings to humans by showing
identical results in healthy volunteers. The underlying mechanism in-
volves increased adenosine levels and subsequent adenosine 2B recep-
tor-mediated enhanced release of IL-10. Hypoxia-induced anti-
inﬂammation may constitute a mechanism to improve the host's
Fig. 8.A2B blockade partially reverses the anti-inﬂammatory effects of the adenosine receptor agonist NECA in endotoxin-stimulated humanwhole blood. (a) Concentrations of IL-10, TNF
and IL-6 in supernatants of whole blood cultures stimulated with endotoxin (10 ng/mL) in the presence and absence of the nonselective adenosine receptor agonist 5′-N-
Ethylcarboxamidoadenosine (NECA) and the selective human A2B receptor antagonist PSB1115. N = 8, Data expressed as mean (±s.e.m.). **P b .01, ***P b .001 (compared with
cultures incubated with the same dose of PSB1115 in the absence of NECA, calculated using paired Student's t-tests). # P b .05, ### P b .001 (compared with cultures incubated with
NECA in the absence of PSB1115, calculated using repeated measures one-way ANOVA with Dunnett's post-hoc tests). (b) Proposed mechanism of hypoxia-induced anti-inﬂammation.
Short-term hypoxia results in augmented adenosine levels and A2B receptor signaling. This results in enhanced IL-10 release via a post-transcriptional mechanism, in turn attenuating
the pro-inﬂammatory cytokine response.
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tolerance to immunopathology, but this requires further study. As
short-term hypoxia is common in critically ill patients, its immunomod-
ulatory effects may affect outcome. Finally, hypoxia and the adenosine
pathway might represent promising therapeutic modalities to modu-
late the immune response.
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